ESPERION THERAPEUTICS INC (ESPR) — insider trading
Health Care · NASDAQ
ESPERION THERAPEUTICS INC (ESPR) has 33 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 33 (latest 2026-07-13).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-13 | Koenig Sheldon L. | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 647,460 | — | — | Form 4 |
| 2026-07-13 | Koenig Sheldon L. | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 753,000 | — | — | Form 4 |
| 2026-07-13 | Koenig Sheldon L. | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 642,000 | — | — | Form 4 |
| 2026-07-13 | Koenig Sheldon L. | Director, Officer (President and CEO) | Disposition to the issuer | 2,121,094 | — | — | Form 4 |
| 2026-07-13 | Halladay Benjamin | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 221,270 | — | — | Form 4 |
| 2026-07-13 | Halladay Benjamin | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 213,000 | — | — | Form 4 |
| 2026-07-13 | Halladay Benjamin | Officer (Chief Financial Officer) | Disposition to the issuer (derivative) | 200,000 | — | — | Form 4 |
| 2026-07-13 | Halladay Benjamin | Officer (Chief Financial Officer) | Disposition to the issuer | 705,410 | — | — | Form 4 |
| 2026-07-13 | Looker Benjamin | Officer (Chief Legal Officer) | Disposition to the issuer (derivative) | 269,230 | — | — | Form 4 |
| 2026-07-13 | Looker Benjamin | Officer (Chief Legal Officer) | Disposition to the issuer (derivative) | 201,000 | — | — | Form 4 |
| 2026-07-13 | Looker Benjamin | Officer (Chief Legal Officer) | Disposition to the issuer (derivative) | 150,000 | — | — | Form 4 |
| 2026-07-13 | Looker Benjamin | Officer (Chief Legal Officer) | Disposition to the issuer | 667,524 | — | — | Form 4 |
| 2026-07-13 | Harlow John B. Jr. | Officer (Chief Commercial Officer) | Disposition to the issuer | 424,536 | — | — | Form 4 |
| 2026-07-13 | THOMPSON JOHN CRAIG | Director | Disposition to the issuer (derivative) | 40,000 | — | — | Form 4 |
| 2026-07-13 | THOMPSON JOHN CRAIG | Director | Disposition to the issuer | 79,873 | — | — | Form 4 |
| 2026-07-13 | Fischer Seth H. Z. | Director | Disposition to the issuer (derivative) | 44,000 | — | — | Form 4 |
| 2026-07-13 | Fischer Seth H. Z. | Director | Disposition to the issuer (derivative) | 32,500 | — | — | Form 4 |
| 2026-07-13 | Fischer Seth H. Z. | Director | Disposition to the issuer (derivative) | 21,000 | — | — | Form 4 |
| 2026-07-13 | Fischer Seth H. Z. | Director | Disposition to the issuer | 141,023 | — | — | Form 4 |
| 2026-07-13 | Shepard Jay | Director | Disposition to the issuer (derivative) | 44,000 | — | — | Form 4 |
| 2026-07-13 | Shepard Jay | Director | Disposition to the issuer (derivative) | 32,500 | — | — | Form 4 |
| 2026-07-13 | Shepard Jay | Director | Disposition to the issuer (derivative) | 21,000 | — | — | Form 4 |
| 2026-07-13 | Shepard Jay | Director | Disposition to the issuer | 164,472 | — | — | Form 4 |
| 2026-07-13 | CARROLL J MARTIN | Director | Disposition to the issuer (derivative) | 44,000 | — | — | Form 4 |
| 2026-07-13 | CARROLL J MARTIN | Director | Disposition to the issuer (derivative) | 32,500 | — | — | Form 4 |
| 2026-07-13 | CARROLL J MARTIN | Director | Disposition to the issuer (derivative) | 21,000 | — | — | Form 4 |
| 2026-07-13 | CARROLL J MARTIN | Director | Disposition to the issuer | 177,523 | — | — | Form 4 |
| 2026-07-13 | Hoffman Robert E. | Director | Disposition to the issuer (derivative) | 7,040 | — | — | Form 4 |
| 2026-07-13 | Hoffman Robert E. | Director | Disposition to the issuer (derivative) | 40,000 | — | — | Form 4 |
| 2026-07-13 | Hoffman Robert E. | Director | Disposition to the issuer | 85,153 | — | — | Form 4 |
| 2026-06-17 | Halladay Benjamin | Officer (Chief Financial Officer) | Open-market sale | 10,773 | $3.16 | $34.0K | Form 4 |
| 2026-06-17 | Koenig Sheldon L. | Director, Officer (President and CEO) | Open-market sale | 53,588 | $3.16 | $169.1K | Form 4 |
| 2026-06-17 | Looker Benjamin | Officer (Chief Legal Officer) | Open-market sale | 11,824 | $3.16 | $37.3K | Form 4 |
Ask the chat about ESPR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ESPERION THERAPEUTICS INC (ESPR).
Last updated 2026-07-13 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.